JMDC (4483) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 FY2025 rose 32% year-over-year to ¥10,725 million, with operating profit up 49% to ¥1,552 million and EBITDA up 38% to ¥2,267 million.

• Profit attributable to owners of parent increased 33% to ¥966 million, and basic EPS rose to ¥14.79 from ¥11.14.

• Growth was led by the Healthcare - Big Data segment, with balanced expansion across Industry, Payers/Individuals, and Medical Service Providers.

• Business for Industry saw accelerated growth, partly due to some sales being recorded earlier than expected, but underlying fundamentals remain robust.

• The transfer of the dispensing pharmacy support business was completed, now classified as discontinued operations.

Financial highlights

• Consolidated revenue rose 32% year-over-year to ¥10,725 million in Q1 FY2025.

• Consolidated EBITDA increased 38% year-over-year to ¥2,267 million, with a margin of 21%.

• Operating profit grew 49% year-over-year to ¥1,552 million; profit attributable to owners of parent up 33% to ¥966 million.

• Gross profit for the quarter was ¥5,500 million, up from ¥4,470 million year-over-year.

• Cash and cash equivalents rose to ¥35,634 million, up ¥3,458 million from March 31, 2025.

Outlook and guidance

• H1 FY2025 revenue forecast at ¥23,000 million, up 24% year-over-year; EBITDA forecast at ¥5,500 million, up 23%.

• Fiscal year 2026 revenue is forecast at ¥50,500 million (up 21%), with operating profit of ¥11,500 million (up 32%) and EBITDA of ¥14,500 million (32.6% margin).

• Healthcare - Big Data segment expected to maintain high growth, with H1 revenue forecast up 28% year-over-year.

• Q2 expected to remain steady, with some Q1 sales brought forward impacting sequential growth, but overall H1 momentum remains strong.

• Guidance for the first half was newly disclosed due to improved business visibility.